NOVADIGM THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.novadigm.net
Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization
Phase 2
Completed
- Conditions
- Staphylococcus Aureus
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- NovaDigm Therapeutics, Inc.
- Target Recruit Count
- 382
- Registration Number
- NCT03455309
- Locations
- 🇺🇸
Fort Benning, Fort Benning, Georgia, United States
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1
Completed
- Conditions
- Vulvovaginal Candidiasis
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- NovaDigm Therapeutics, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT01926028
- Locations
- 🇺🇸
Precision Trials LLC, Phoenix, Arizona, United States
🇺🇸Arkansas Women's Center, Little Rock, Arkansas, United States
🇺🇸Women's Health Care Research Corp, San Diego, California, United States
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
Phase 1
Completed
- Conditions
- Staphylococcal InfectionsYeast InfectionsCandidiasis
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- NovaDigm Therapeutics, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT01447407
- Locations
- 🇺🇸
Cetero Research Clinical Site, Fargo, North Dakota, United States
Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida
Phase 1
Completed
- Conditions
- Staphylococcal InfectionsCandidiasis
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2012-05-22
- Lead Sponsor
- NovaDigm Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01273922
- Locations
- 🇺🇸
Cetero, Fargo, North Dakota, United States
News
No news found